Peregrine Knew Cancer Drug Trials Were Bunk, 9th Circ. Told
A Peregrine Pharmaceuticals shareholder urged the Ninth Circuit on Wednesday to revive his stock-drop class action alleging the drugmaker puffed up its share price with false positive news about its lung...To view the full article, register now.
Already a subscriber? Click here to view full article